Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-17
    E.g., 2018-10-17



6233 items
2:45 PM, Oct 12, 2018  |  BioCentury | Finance

Versant seizes the RNA moment

As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics. Versant co-led Gotham’s $54 million series A...
1:57 PM, Oct 12, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least three profitable biotechs and pharmas are slated to report earnings this week. (A) Before U.S. markets open; during trading hours in Europe CompanyDatePre/post mkt3Q18 EPS est3Q17 EPSExpected chgJohnson & Johnson (NYSE:JNJ)10/16Pre$2.03$1.907%Roche (SIX:ROG;...
1:27 PM, Oct 12, 2018  |  BioCentury | Finance

Spinning out Sitryx

With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the first start-up to emerge from the Immunology Network at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The round, which closed on...
8:03 AM, Oct 12, 2018  |  BioCentury | Finance

A Glympse at drug response

Investors poured $22 million into Glympse Bio Inc.’s series A round after the company established plans to apply its non-invasive sensors to both diagnostics and drug response monitoring. Polaris Partners and Arch Venture Partners co-led...
6:19 PM, Oct 05, 2018  |  BioCentury | Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs have pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
6:14 PM, Oct 05, 2018  |  BioCentury | Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market for investors through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18...
5:48 PM, Oct 05, 2018  |  BioCentury | Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
4:20 PM, Oct 05, 2018  |  BioCentury | Finance

Fruitful partnerships

Arix Bioscience plc (LSE:ARIX) leveraged its partnership with Takeda Ventures to co-lead a $58 million series A round for antibody-drug company VelosBio Inc., a sign that the VC’s strategic partnerships are finally bearing fruit. Also participating...
4:05 PM, Oct 05, 2018  |  BioCentury | Finance

Risk-sharing at scale

By operating under the Blackstone umbrella, Clarus Ventures will be able to significantly scale up its risk-sharing investment strategy. On Oct. 4, private equity firm Blackstone announced plans to acquire Clarus for undisclosed terms. Clarus co-founder...
9:04 AM, Oct 05, 2018  |  BioCentury | Finance

Modis’ mitochondrial modification

Compassionate use data from its lead program enabled rare genetic disease company Modis Therapeutics Inc. to attract $30 million in series A funding co-led by F-Prime Capital Partners and OrbiMed Advisors. Founding investor Aceras Life...